At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
lonafarnib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib/Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus
In Brief
A Phase 2 clinical trial evaluating lonafarnib and Ritonavir for Chronic Delta Hepatitis. Completed, enrolled 15 participants.
Detailed Summary
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Delta Hepatitis
Countries--
CollaboratorsHannover Medical School
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionAug 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedAug 19, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2016
Study CompletionFeb 9, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.9 years ago
Interventions
lonafarnibdrug
antiviral farnesyltransferase inhibitor
Ritonavirdrug
Cytochromes P450 3A4 inhibitor used to boost lonafarnib